{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:26:43Z","timestamp":1794288403526,"version":"4.9.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T00:00:00Z","timestamp":1579824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA169133"],"award-info":[{"award-number":["R01CA169133"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA103320"],"award-info":[{"award-number":["R01CA103320"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA211229"],"award-info":[{"award-number":["R01CA211229"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute"},{"DOI":"10.13039\/100000072","name":"U.S. Department of Health & Human Services | NIH | National Institute of Dental and Craniofacial Research","doi-asserted-by":"publisher","award":["R21DE028716"],"award-info":[{"award-number":["R21DE028716"]}],"id":[{"id":"10.13039\/100000072","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"U.S. Department of Health & Human Services | NIH | NIH Office of the Director","doi-asserted-by":"publisher","award":["1S10OD021805-01"],"award-info":[{"award-number":["1S10OD021805-01"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>CD73, an ecto-5\u2032-nucleotidase (NT5E), serves as an immune checkpoint by generating adenosine (ADO), which suppresses immune activation through the A<jats:sub>2A<\/jats:sub> receptor. Elevated CD73 levels in tumor tissues correlate with poor clinical outcomes. However, the crucial source of CD73 activity within the tumor microenvironment remains unspecified. Here, we demonstrate that cancer-associated fibroblasts (CAFs) constitute the prominent CD73<jats:sup>hi<\/jats:sup> population in human colorectal cancers (CRCs) and two CD73<jats:sup>\u2212<\/jats:sup> murine tumor models, including a modified CRC. Clinically, high CAF abundancy in CRC tissues correlates strongly with elevated CD73 activity and poor prognosis. Mechanistically, CAF-CD73 expression is enhanced via an ADO-A<jats:sub>2B<\/jats:sub> receptor-mediated feedforward circuit triggered by tumor cell death, which enforces the CD73-checkpoint. Simultaneous inhibition of A<jats:sub>2A<\/jats:sub> and A<jats:sub>2B<\/jats:sub> pathways with CD73-neutralization synergistically enhances antitumor immunity in CAF-rich tumors. Therefore, the strategic and effective targeting of both the A<jats:sub>2B<\/jats:sub>-mediated ADO-CAF-CD73 feedforward circuit and A<jats:sub>2A<\/jats:sub>-mediated immune suppression is crucial for improving therapeutic outcomes.<\/jats:p>","DOI":"10.1038\/s41467-019-14060-x","type":"journal-article","created":{"date-parts":[[2020,1,24]],"date-time":"2020-01-24T11:03:06Z","timestamp":1579863786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":174,"title":["CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3614-1329","authenticated-orcid":false,"given":"Miao","family":"Yu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1996-944X","authenticated-orcid":false,"given":"Lei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Libin","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3879-6599","authenticated-orcid":false,"given":"Chang-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagelu R.","family":"Achyut","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madison","family":"Canning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningchun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2902-3671","authenticated-orcid":false,"given":"Ali S.","family":"Arbab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4963-6619","authenticated-orcid":false,"given":"Roni J.","family":"Bollag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulo C.","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mellor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1137-3390","authenticated-orcid":false,"given":"Huidong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Munn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2800-6039","authenticated-orcid":false,"given":"Yan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,24]]},"reference":[{"key":"14060_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s11302-005-5302-5","volume":"2","author":"SP Colgan","year":"2006","unstructured":"Colgan, S. P., Eltzschig, H. K., Eckle, T. & Thompson, L. F. Physiological roles for ecto-5\u2019-nucleotidase (CD73). Purinergic Signal. 2, 351\u2013360 (2006).","journal-title":"Purinergic Signal."},{"key":"14060_CR2","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.it.2012.02.009","volume":"33","author":"PA Beavis","year":"2012","unstructured":"Beavis, P. A., Stagg, J., Darcy, P. K. & Smyth, M. J. CD73: a potent suppressor of antitumor immune responses. Trends Immunol. 33, 231\u2013237 (2012).","journal-title":"Trends Immunol."},{"key":"14060_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/imr.12528","volume":"276","author":"B Allard","year":"2017","unstructured":"Allard, B., Longhi, M. S., Robson, S. C. & Stagg, J. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol. Rev. 276, 121\u2013144 (2017).","journal-title":"Immunol. Rev."},{"key":"14060_CR4","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/414916a","volume":"414","author":"A Ohta","year":"2001","unstructured":"Ohta, A. & Sitkovsky, M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916\u2013920 (2001).","journal-title":"Nature"},{"key":"14060_CR5","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","volume":"5","author":"A Ohta","year":"2014","unstructured":"Ohta, A. & Sitkovsky, M. Extracellular adenosine-mediated modulation of regulatory T cells. Front. Immunol. 5, 304 (2014).","journal-title":"Front. Immunol."},{"key":"14060_CR6","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1182\/blood-2007-03-081646","volume":"111","author":"PE Zarek","year":"2008","unstructured":"Zarek, P. E. et al. A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood 111, 251\u2013259 (2008).","journal-title":"Blood"},{"key":"14060_CR7","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1158\/1078-0432.CCR-15-1181","volume":"22","author":"BG Leclerc","year":"2016","unstructured":"Leclerc, B. G. et al. CD73 expression is an independent prognostic factor in prostate cancer. Clin. Cancer Res. 22, 158\u2013166 (2016).","journal-title":"Clin. Cancer Res."},{"key":"14060_CR8","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.1182\/blood-2011-08-374728","volume":"118","author":"S Serra","year":"2011","unstructured":"Serra, S. et al. CD73-generated extracellular adenosine in chronic lymphocytic leukemia creates local conditions counteracting drug-induced cell death. Blood 118, 6141\u20136152 (2011).","journal-title":"Blood"},{"key":"14060_CR9","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/0008-5472.CAN-14-3569","volume":"75","author":"M Turcotte","year":"2015","unstructured":"Turcotte, M. et al. CD73 is associated with poor prognosis in high-grade serous ovarian cancer. Cancer Res. 75, 4494\u20134503 (2015).","journal-title":"Cancer Res."},{"key":"14060_CR10","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1158\/0008-5472.CAN-17-0395","volume":"77","author":"J Reinhardt","year":"2017","unstructured":"Reinhardt, J. et al. MAPK signaling and inflammation link melanoma phenotype switching to induction of CD73 during immunotherapy. Cancer Res. 77, 4697\u20134709 (2017).","journal-title":"Cancer Res."},{"key":"14060_CR11","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/ni.3868","volume":"18","author":"T Maj","year":"2017","unstructured":"Maj, T. et al. Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat. Immunol. 18, 1332\u20131341 (2017).","journal-title":"Nat. Immunol."},{"key":"14060_CR12","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1172\/JCI45559","volume":"121","author":"L Wang","year":"2011","unstructured":"Wang, L. et al. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J. Clin. Invest. 121, 2371\u20132382 (2011).","journal-title":"J. Clin. Invest."},{"key":"14060_CR13","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1158\/0008-5472.CAN-10-4246","volume":"71","author":"J Stagg","year":"2011","unstructured":"Stagg, J. et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 71, 2892\u20132900 (2011).","journal-title":"Cancer Res."},{"key":"14060_CR14","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/0008-5472.CAN-12-0420","volume":"72","author":"J Stagg","year":"2012","unstructured":"Stagg, J. et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 72, 2190\u20132196 (2012).","journal-title":"Cancer Res."},{"key":"14060_CR15","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1101\/gad.279737.116","volume":"30","author":"P Gascard","year":"2016","unstructured":"Gascard, P. & Tlsty, T. D. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 30, 1002\u20131019 (2016).","journal-title":"Genes Dev."},{"key":"14060_CR16","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nrc.2016.73","volume":"16","author":"R Kalluri","year":"2016","unstructured":"Kalluri, R. The biology and function of fibroblasts in cancer. Nat. Rev. Cancer 16, 582\u2013598 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"14060_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/nri3902","volume":"15","author":"SJ Turley","year":"2015","unstructured":"Turley, S. J., Cremasco, V. & Astarita, J. L. Immunological hallmarks of stromal cells in the tumour microenvironment. Nat. Rev. Immunol. 15, 669\u2013682 (2015).","journal-title":"Nat. Rev. Immunol."},{"key":"14060_CR18","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1038\/nature03096","volume":"432","author":"NA Bhowmick","year":"2004","unstructured":"Bhowmick, N. A., Neilson, E. G. & Moses, H. L. Stromal fibroblasts in cancer initiation and progression. Nature 432, 332\u2013337 (2004).","journal-title":"Nature"},{"key":"14060_CR19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","volume":"121","author":"A Orimo","year":"2005","unstructured":"Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion. Cell 121, 335\u2013348 (2005).","journal-title":"Cell"},{"key":"14060_CR20","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1084\/jem.20140692","volume":"211","author":"D Ohlund","year":"2014","unstructured":"Ohlund, D., Elyada, E. & Tuveson, D. Fibroblast heterogeneity in the cancer wound. J. Exp. Med. 211, 1503\u20131523 (2014).","journal-title":"J. Exp. Med."},{"key":"14060_CR21","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccr.2011.01.020","volume":"19","author":"M Quante","year":"2011","unstructured":"Quante, M. et al. Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell 19, 257\u2013272 (2011).","journal-title":"Cancer Cell"},{"key":"14060_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/14653240600855905","volume":"8","author":"M Dominici","year":"2006","unstructured":"Dominici, M. et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 8, 315\u2013317 (2006).","journal-title":"Cytotherapy"},{"key":"14060_CR23","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/ng.3225","volume":"47","author":"A Calon","year":"2015","unstructured":"Calon, A. et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer. Nat. Genet. 47, 320\u2013329 (2015).","journal-title":"Nat. Genet."},{"key":"14060_CR24","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/nm.3175","volume":"19","author":"A Sadanandam","year":"2013","unstructured":"Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619\u2013625 (2013).","journal-title":"Nat. Med."},{"key":"14060_CR25","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1038\/ni.2262","volume":"13","author":"D Malhotra","year":"2012","unstructured":"Malhotra, D. et al. Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nat. Immunol. 13, 499\u2013510 (2012).","journal-title":"Nat. Immunol."},{"key":"14060_CR26","doi-asserted-by":"publisher","first-page":"5652","DOI":"10.1158\/0008-5472.CAN-17-0707","volume":"77","author":"M Turcotte","year":"2017","unstructured":"Turcotte, M. et al. CD73 promotes resistance to HER2\/ErbB2 antibody therapy. Cancer Res. 77, 5652\u20135663 (2017).","journal-title":"Cancer Res."},{"key":"14060_CR27","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.3892\/or.2015.4512","volume":"35","author":"R Wu","year":"2016","unstructured":"Wu, R. et al. Effects of CD73 on human colorectal cancer cell growth in vivo and in vitro. Oncol. Rep. 35, 1750\u20131756 (2016).","journal-title":"Oncol. Rep."},{"key":"14060_CR28","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/jso.23056","volume":"106","author":"XR Wu","year":"2012","unstructured":"Wu, X. R. et al. High expression of CD73 as a poor prognostic biomarker in human colorectal cancer. J. Surg. Oncol. 106, 130\u2013137 (2012).","journal-title":"J. Surg. Oncol."},{"key":"14060_CR29","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/978-1-4939-3023-4_22","volume":"876","author":"P Vaupel","year":"2016","unstructured":"Vaupel, P. & Mayer, A. Hypoxia-driven adenosine accumulation: a crucial microenvironmental factor promoting tumor progression. Adv. Exp. Med. Biol. 876, 177\u2013183 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"14060_CR30","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s00066-016-0948-1","volume":"192","author":"P Vaupel","year":"2016","unstructured":"Vaupel, P. & Multhoff, G. Adenosine can thwart antitumor immune responses elicited by radiotherapy: therapeutic strategies alleviating protumor ADO activities. Strahlenther. Onkol. 192, 279\u2013287 (2016).","journal-title":"Strahlenther. Onkol."},{"key":"14060_CR31","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.addr.2015.07.007","volume":"99","author":"G Ishii","year":"2016","unstructured":"Ishii, G., Ochiai, A. & Neri, S. Phenotypic and functional heterogeneity of cancer-associated fibroblast within the tumor microenvironment. Adv. Drug Deliv. Rev. 99, 186\u2013196 (2016).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"14060_CR32","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nature04871","volume":"441","author":"J Pouyssegur","year":"2006","unstructured":"Pouyssegur, J., Dayan, F. & Mazure, N. M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441, 437\u2013443 (2006).","journal-title":"Nature"},{"key":"14060_CR33","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/S1535-6108(03)00194-6","volume":"4","author":"B Blouw","year":"2003","unstructured":"Blouw, B. et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 4, 133\u2013146 (2003).","journal-title":"Cancer Cell"},{"key":"14060_CR34","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1172\/JCI0215337","volume":"110","author":"K Synnestvedt","year":"2002","unstructured":"Synnestvedt, K. et al. Ecto-5\u2019-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia. J. Clin. Invest. 110, 993\u20131002 (2002).","journal-title":"J. Clin. Invest."},{"key":"14060_CR35","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1146\/annurev.immunol.22.012703.104731","volume":"22","author":"MV Sitkovsky","year":"2004","unstructured":"Sitkovsky, M. V. et al. Physiological control of immune response and inflammatory tissue damage by hypoxia-inducible factors and adenosine A2A receptors. Annu. Rev. Immunol. 22, 657\u2013682 (2004).","journal-title":"Annu. Rev. Immunol."},{"key":"14060_CR36","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","volume":"29","author":"B Allard","year":"2016","unstructured":"Allard, B., Beavis, P. A., Darcy, P. K. & Stagg, J. Immunosuppressive activities of adenosine in cancer. Curr. Opin. Pharm. 29, 7\u201316 (2016).","journal-title":"Curr. Opin. Pharm."},{"key":"14060_CR37","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nrd3955","volume":"12","author":"JF Chen","year":"2013","unstructured":"Chen, J. F., Eltzschig, H. K. & Fredholm, B. B. Adenosine receptors as drug targets\u2014what are the challenges? Nat. Rev. Drug Discov. 12, 265\u2013286 (2013).","journal-title":"Nat. Rev. Drug Discov."},{"key":"14060_CR38","doi-asserted-by":"publisher","unstructured":"Bezu, L. et al. Combinatorial strategies for the induction of immunogenic cell death. Front. Immunol. 6, https:\/\/doi.org\/10.3389\/fimmu.2015.00187 (2015).","DOI":"10.3389\/fimmu.2015.00187"},{"key":"14060_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/nrc3958","volume":"15","author":"HE Barker","year":"2015","unstructured":"Barker, H. E., Paget, J. T., Khan, A. A. & Harrington, K. J. The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence. Nat. Rev. Cancer 15, 409\u2013425 (2015).","journal-title":"Nat. Rev. Cancer"},{"key":"14060_CR40","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1084\/jem.20131195","volume":"210","author":"F Lotti","year":"2013","unstructured":"Lotti, F. et al. Chemotherapy activates cancer-associated fibroblasts to maintain colorectal cancer-initiating cells by IL-17A. J. Exp. Med. 210, 2851\u20132872 (2013).","journal-title":"J. Exp. Med."},{"key":"14060_CR41","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1158\/0008-5472.CAN-17-0524","volume":"78","author":"J Tommelein","year":"2018","unstructured":"Tommelein, J. et al. Radiotherapy-activated cancer-associated fibroblasts promote tumor progression through paracrine IGF1R activation. Cancer Res. 78, 659\u2013670 (2018).","journal-title":"Cancer Res."},{"key":"14060_CR42","doi-asserted-by":"publisher","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","volume":"115","author":"D Samanta","year":"2018","unstructured":"Samanta, D. et al. Chemotherapy induces enrichment of CD47+CD73+PDL1+ immune evasive triple-negative breast cancer cells. Proc. Natl Acad. Sci. USA 115, E1239\u2013E1248 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14060_CR43","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.1158\/0008-5472.CAN-16-2832","volume":"77","author":"G Guo","year":"2017","unstructured":"Guo, G., Yu, M., Xiao, W., Celis, E. & Cui, Y. Local activation of p53 in the tumor microenvironment overcomes immune suppression and enhances antitumor immunity. Cancer Res. 77, 2292\u20132305 (2017).","journal-title":"Cancer Res."},{"key":"14060_CR44","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","volume":"30","author":"A Young","year":"2016","unstructured":"Young, A. et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30, 391\u2013403 (2016).","journal-title":"Cancer Cell"},{"key":"14060_CR45","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","volume":"27","author":"L Topalian Suzanne","year":"2015","unstructured":"Topalian Suzanne, L., Drake Charles, G. & Pardoll Drew, M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450\u2013461 (2015).","journal-title":"Cancer Cell"},{"key":"14060_CR46","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1016\/j.cell.2017.07.024","volume":"170","author":"SC Wei","year":"2017","unstructured":"Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120\u20131133.e17 (2017).","journal-title":"Cell"},{"key":"14060_CR47","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1038\/nm.3394","volume":"19","author":"DF Quail","year":"2013","unstructured":"Quail, D. F. & Joyce, J. A. Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423\u20131437 (2013).","journal-title":"Nat. Med."},{"key":"14060_CR48","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1158\/0008-5472.CAN-12-3810","volume":"73","author":"G Guo","year":"2013","unstructured":"Guo, G. et al. Trp53 inactivation in the tumor microenvironment promotes tumor progression by expanding the immunosuppressive lymphoid-like stromal network. Cancer Res. 73, 1668\u20131675 (2013).","journal-title":"Cancer Res."},{"key":"14060_CR49","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1158\/0008-5472.CAN-09-3109","volume":"70","author":"D Jin","year":"2010","unstructured":"Jin, D. et al. CD73 on tumor cells impairs antitumor T-cell responses: a novel mechanism of tumor-induced immune suppression. Cancer Res. 70, 2245\u20132255 (2010).","journal-title":"Cancer Res."},{"key":"14060_CR50","doi-asserted-by":"publisher","first-page":"4905","DOI":"10.1158\/1078-0432.CCR-13-1694","volume":"19","author":"MR Freeman","year":"2013","unstructured":"Freeman, M. R., Li, Q. & Chung, L. W. Can stroma reaction predict cancer lethality? Clin. Cancer Res. 19, 4905\u20134907 (2013).","journal-title":"Clin. Cancer Res."},{"key":"14060_CR51","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-16-0544","volume":"76","author":"D Mittal","year":"2016","unstructured":"Mittal, D. et al. Adenosine 2B receptor expression on cancer cells promotes metastasis. Cancer Res. 76, 4372\u20134382 (2016).","journal-title":"Cancer Res."},{"key":"14060_CR52","doi-asserted-by":"publisher","first-page":"860","DOI":"10.4161\/cbt.25643","volume":"14","author":"M Mediavilla-Varela","year":"2013","unstructured":"Mediavilla-Varela, M. et al. Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth. Cancer Biol. Ther. 14, 860\u2013868 (2013).","journal-title":"Cancer Biol. Ther."},{"key":"14060_CR53","doi-asserted-by":"publisher","first-page":"3045","DOI":"10.1158\/0008-5472.CAN-15-2310","volume":"76","author":"F Wirsdorfer","year":"2016","unstructured":"Wirsdorfer, F. et al. Extracellular adenosine production by ecto-5\u2019-nucleotidase (CD73) enhances radiation-induced lung fibrosis. Cancer Res. 76, 3045\u20133056 (2016).","journal-title":"Cancer Res."},{"key":"14060_CR54","doi-asserted-by":"publisher","first-page":"11091","DOI":"10.1073\/pnas.1222251110","volume":"110","author":"S Loi","year":"2013","unstructured":"Loi, S. et al. CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc. Natl Acad. Sci. USA 110, 11091\u201311096 (2013).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14060_CR55","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1007\/s00109-014-1189-3","volume":"92","author":"SM Hatfield","year":"2014","unstructured":"Hatfield, S. M. et al. Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1alpha-dependent and extracellular adenosine-mediated tumor protection. J. Mol. Med. 92, 1283\u20131292 (2014).","journal-title":"J. Mol. Med."},{"key":"14060_CR56","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1073\/pnas.0908801107","volume":"107","author":"J Stagg","year":"2010","unstructured":"Stagg, J. et al. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc. Natl Acad. Sci. USA 107, 1547\u20131552 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"14060_CR57","doi-asserted-by":"publisher","first-page":"198","DOI":"10.4049\/jimmunol.1101845","volume":"188","author":"C Cekic","year":"2012","unstructured":"Cekic, C. et al. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J. Immunol. 188, 198\u2013205 (2012).","journal-title":"J. Immunol."},{"key":"14060_CR58","doi-asserted-by":"publisher","first-page":"e1001453","DOI":"10.1371\/journal.pmed.1001453","volume":"10","author":"L Marisa","year":"2013","unstructured":"Marisa, L. et al. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value. PLoS Med. 10, e1001453 (2013).","journal-title":"PLoS Med."},{"key":"14060_CR59","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-15-1507","volume":"22","author":"PS Hegde","year":"2016","unstructured":"Hegde, P. S., Karanikas, V. & Evers, S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin. Cancer Res. 22, 1865\u20131874 (2016).","journal-title":"Clin. Cancer Res."},{"key":"14060_CR60","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1172\/JCI89455","volume":"127","author":"PA Beavis","year":"2017","unstructured":"Beavis, P. A. et al. Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy. J. Clin. Investig. 127, 929\u2013941 (2017).","journal-title":"J. Clin. Investig."},{"key":"14060_CR61","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/j.drudis.2017.06.005","volume":"22","author":"L Antonioli","year":"2017","unstructured":"Antonioli, L. et al. Switching off CD73: a way to boost the activity of conventional and targeted antineoplastic therapies. Drug Discov. Today 22, 1686\u20131696 (2017).","journal-title":"Drug Discov. Today"},{"key":"14060_CR62","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1093\/bioinformatics\/btp120","volume":"25","author":"C Trapnell","year":"2009","unstructured":"Trapnell, C., Pachter, L. & Salzberg, S. L. TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25, 1105\u20131111 (2009).","journal-title":"Bioinformatics"},{"key":"14060_CR63","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1038\/nbt.1621","volume":"28","author":"C Trapnell","year":"2010","unstructured":"Trapnell, C. et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat. Biotechnol. 28, 511\u2013515 (2010).","journal-title":"Nat. Biotechnol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14060-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14060-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14060-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T17:29:31Z","timestamp":1670261371000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-14060-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,24]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["14060"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-14060-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,24]]},"assertion":[{"value":"23 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"515"}}